AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors
November 19 2019 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of
Scarlett Spring to its Board of Directors. Ms. Spring brings to
AVEO extensive sales, commercial, and leadership experience in the
biopharmaceutical and life sciences industries.
“It is a pleasure to welcome Scarlett to our Board of
Directors,” said Michael Bailey, president and chief executive
officer of AVEO. “Her experience and proven track record across a
wide spectrum of roles within the industry will be of great value
at this crucial juncture for AVEO. We look forward to leveraging
her expertise as we lay the groundwork for our potential transition
to a commercial entity and continue to execute on advancing our
pipeline.”
"I am excited to be joining the Board of Directors at such an
essential time for AVEO," said Ms. Spring. “AVEO has a unique and
meaningful opportunity in tivozanib to potentially impact the
treatment of kidney cancer. I look forward to working alongside the
Board and management team to help ensure that tivozanib and the
AVEO pipeline realize their full potential.”
Ms. Spring currently serves as Co-Founder and Chief Executive
Officer of TapRoot Interventions & Solutions, a platform
technology company focused on providing real-time, tailored
interventions to caregivers managing patients with Alzheimer’s and
dementia behaviors. She previously served as President and Chief
Commercial Officer for VisionGate, Inc., a clinical-stage
pharmaceutical and diagnostics company developing products for the
early detection, prevention, and treatment of lung cancer. Prior to
VisionGate, Ms. Spring served in various sales and commercial roles
of increasing responsibility at Merck and AstraZeneca
Pharmaceuticals. At AstraZeneca, she was involved in the successful
launches of Prilosec®, Nexium®, Crestor® and Iressa®, and managed
the hormonal portfolio for AstraZeneca Oncology.
Ms. Spring also previously served as Executive Vice President
and Chief Operating Officer of the Greater Phoenix Economic
Council. She currently serves on the Arizona Bioscience Board and
Risk Capital Committee of the Flinn Foundation, as well as on the
Boards of Republic Bank of Arizona and the Arizona Sports and
Tourism Authority. She received a Bachelor’s degree in Marketing
from the University of Texas at Austin and a Master’s in Business
Administration from Pepperdine University.
About AVEO
AVEO Pharmaceuticals is a biopharmaceutical company seeking to
advance targeted medicines for oncology and other unmet medical
needs. The Company’s lead candidate is tivozanib, a potent,
selective, long half-life inhibitor of vascular endothelial growth
factor 1, 2 and 3 receptors, which AVEO is seeking to develop and
commercialize in North America as a treatment for renal cell
carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers.
Tivozanib (FOTIVDA®) is approved by the European Commission for the
treatment of adult patients with advanced RCC in the European Union
plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks
to leverage partnerships to develop and commercialize its pipeline
of products and product candidates, including tivozanib in oncology
and other indications in various geographies, and ficlatuzumab (HGF
MAb) in head and neck cancer, pancreatic cancer and acute myeloid
leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3
MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates
being developed for various oncology indications.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. The words
“anticipate,” “believe,” “expect,” “intend,” “may,” “plan,”
“potential,” “could,” “should,” “would,” “seek,” “look forward,”
“advance,” “goal,” “strategy,” or the negative of these terms or
other similar expressions, are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include,
among others, statements about: the potential for tivozanib as a
treatment option for patients with relapsed/refractory or advanced
RCC; the potential efficacy, safety, and tolerability of tivozanib,
both as a stand-alone drug candidate and in combination with other
therapies in several indications; AVEO’s plans and strategies for
commercialization of tivozanib in the United States and Europe; and
AVEO’s strategy, prospects, plans and objectives for its product
candidates and for the Company generally. AVEO has based its
expectations and estimates on assumptions that may prove to be
incorrect. As a result, readers are cautioned not to place undue
reliance on these expectations and estimates. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that AVEO
makes due to a number of important factors, including risks
relating to: AVEO’s ability, and the ability of its licensees, to
demonstrate to the satisfaction of applicable regulatory agencies
such as the FDA the safety, efficacy and clinically meaningful
benefit of AVEO’s product candidates, including, in particular,
tivozanib and ficlatuzumab; AVEO’s ability to successfully file an
NDA for tivozanib; and AVEO’s ability to enter into and maintain
its third party collaboration and license agreements, and its
ability, and the ability of its strategic partners, to achieve
development and commercialization objectives under these
arrangements. AVEO faces other risks relating to its business as
well, including risks relating to the timing and costs of seeking
and obtaining regulatory approval; AVEO’s and its collaborators’
ability to successfully enroll and complete clinical trials; AVEO’s
ability to maintain compliance with regulatory requirements
applicable to its product candidates; AVEO’s ability to obtain and
maintain adequate protection for intellectual property rights
relating to its product candidates; AVEO’s ability to successfully
implement its strategic plans; AVEO’s ability to raise the
substantial additional funds required to achieve its goals,
including those goals pertaining to the development and
commercialization of tivozanib; unplanned capital requirements;
adverse general economic and industry conditions; competitive
factors; and those risks discussed in the sections titled “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Liquidity and Capital
Resources” included in AVEO’s quarterly and annual reports on file
with the Securities and Exchange Commission (SEC) and in other
filings that AVEO makes with the SEC. The forward-looking
statements in this press release represent AVEO’s views as of the
date of this press release, and subsequent events and developments
may cause its views to change. While AVEO may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as
representing AVEO's views as of any date other than the date of
this press release. Any reference to AVEO’s website address in this
press release is intended to be an inactive textual reference only
and not an active hyperlink.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191119005218/en/
AVEO: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024